Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cohesion Sale Drives Shares In September; O-T-C Index Composite Declines

This article was originally published in The Gray Sheet

Executive Summary

Cohesion Technologies shares spiked 64% on Sept. 30, the day the firm announced its acquisition by Angiotech Pharmaceuticals. The issue closed September at $3.86, an 81% gain for the month overall

You may also be interested in...



Angiotech CoSeal

U.S. clinical trials for drug-coated version of the polymer vascular surgical sealant are scheduled to begin in 2004, the company says. Angiotech Pharmaceuticals' acquisition of CoSeal developer Cohesion Technologies was completed Feb. 3 (1"The Gray Sheet" Oct. 7, 2002, p. 29). A "premixed" version of the device recently received PMA supplement approval, allowing the sealant to be loaded with an Angiotech pharmaceutical to prevent surgical adhesions. Current CoSeal improvements include easier preparation, a life span increase from 45 minutes to two hours and the ability to be stored at room temperature...

Angiotech CoSeal

U.S. clinical trials for drug-coated version of the polymer vascular surgical sealant are scheduled to begin in 2004, the company says. Angiotech Pharmaceuticals' acquisition of CoSeal developer Cohesion Technologies was completed Feb. 3 (1"The Gray Sheet" Oct. 7, 2002, p. 29). A "premixed" version of the device recently received PMA supplement approval, allowing the sealant to be loaded with an Angiotech pharmaceutical to prevent surgical adhesions. Current CoSeal improvements include easier preparation, a life span increase from 45 minutes to two hours and the ability to be stored at room temperature...

Medtronic/RTI

Revised human allograft exclusive worldwide distribution agreement includes an option for Medtronic Sofamor Danek to purchase up to $10 mil. of Regeneration Technologies stock. The pact, which relates to RTI's specialty tissue allografts and bone paste used in spinal surgery, also calls for an increase in the licensing and transfer fees paid by Medtronic from 30% to "40-50%," RTI says. The restructured agreement reflects "the value of RTI's proprietary technology," including the BioCleanse tissue sterilization process, according to a June 19 RTI release. A next generation version of the BioCleanse process, introduced June 12, sterilizes tissue from single donors in separate chambers, eliminating the need to batch tissue from multiple donors...

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel